Approximately 187.23 Bn active pharmaceutical ingredients are expected to be sold in 2020, growing at a CAGR of 6.42% to 255.56 Bn by 2025 as per the active pharmaceutical manufacturing report.
Market Dynamics
Active Pharmaceutical Ingredient (API) market growth is largely due to factors such as an increase in chronic diseases and the geriatric population. The increasing investment of pharmaceutical corporations in API formulations at lower prices in developing countries, as well as the increasing dependence on API formulations, is also contributing to the growth of the market.
Moreover, the expanding market for bio-similar and the advances in API manufacturing are creating lucrative business opportunities.
Unfortunately, price controls and the high costs of manufacturing APIs limit the growth of the market.
In developing countries such as India, several private and public initiatives are expected to drive the market’s growth. Making APIs in India is promoted as part of the “Make in India” program.
Market growth is also likely to be aided by the presence of leading players and government initiatives aimed at developing pharmaceuticals in various regions. In the Asia Pacific, as well as the Middle East and Africa, market forces are driving the demand for economic treatment strategies. API sales are likely to be boosted by the growing popularity and adoption of online pharmacies.
In detail about the Lutetium-177 (Lu-177) market and Pipeline Analysis
Lutetium-177 (Lu-177) market and Pipeline Analysis – forecast to 2026 provides information about Lu-177 based therapies for the treatment of cancers such as prostate cancer, GEP-NET, lung cancer to name a few. Besides marketed products, the report also covers drugs at various stages of development i.e. preclinical, discovery, and clinical. In the pipeline, there are Lu-177 labelled monoclonal antibodies and peptides that are being tested clinically, as well as FDA and CE-approved products (Lutathera).
This report is intended for Radiopharmaceutical and Biotechnology companies, Service providers, Individual researchers, Academic institutions, Investors, and other interested parties to source and analyze Lu-177 licensing opportunities and collaborations. Several molecules that will be launched in the next few years are also described in the report. The report consists of the following sections
- Market Analysis
- Specifically, the market size of the prostate cancer and global GEP-NET markets is detailed across the sections of the market analysis along with the number of eligible patients, the market penetration, total addressable market (TAM), and forecasts for the isotope market from 2019 to 2026.
- Players that use the Lu-177 and their production capacity
- Market dynamics for Lu-177.
- Analysis of deals related to Lu-177.
- The situation of the Lu-177 market in terms of funding
- Rates (GEP-NET & prostate cancer) for global, North America, Europe, Asia, and the Rest of the World.
- Pipeline Analysis
- Types of molecules analyzed by the pipeline
- Pipeline analysis of monoclonal antibodies
- Analyze of peptide-labelled pipelines
- Analyses of top players’ pipelines and their molecules
- Types of molecules analyzed by the pipeline
- Key Players Analysis
- A detailed analysis of key players with regards to Lu-177 provides an in-depth knowledge of the pipelines with Lu-177 in the development phase, as well as deals entered by those companies.
- An overview of global key players
- Players in the pipeline (discoveries, preclinical & clinical trials)
- A global key players deal (a collaboration or partnership, a license, a grant, a fund)
Thus, here is the complete synopsis of lutetium-177 pipeline analysis report.
About The Author
